Previous 10 | Next 10 |
InVivo Therapeutics Holdings ( NVIV ) +106% . GreenLight Biosciences ( GRNA ) +94% . NanoViricides ( NNVC ) +48% stock skyrockets 50% on start of drug development program for monkeypox. Exicure ( XCUR ) +39% . Global Blood Therapeuti...
Gainers: Kaspien Holdings ( KSPN ) +136% . Heart Test Laboratories ( HSCS ) +92% . Poseida Therapeutics ( PSTX ) +74% . Eargo ( EAR ) +73% . Ping Identity ( PING ) +60% . Applied DNA ( APDN ) +53% . Golden Sun ( ...
Applied DNA Sciences ( APDN ) +116% . Poseida Therapeutics ( PSTX ) +81% . Ping Identity Holding ( PING ) +60% Non-GAAP EPS of -$0.34 misses by $0.22, revenue of $72.03M misses by $1.27M. Alnylam Pharmaceuticals ( ALNY ) +47% as Phase 3 tr...
Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...
AMTD IDEA ( AMTD ) +323% . 36Kr Holdings ( KRKR ) +70% . Quoin Pharmaceuticals ( QNRX ) +54% . Intelligent Living ( ILAG ) +40% . Getty Images Holdings ( GETY ) +24% stock rallies for second day, shares gain 19%. Innoviz ...
Gainers: Virax Biolabs ( VRAX ) +62% . Aethlon Medical ( AEMD ) +46% . GeoVax Labs ( GOVX ) +46% . Celyad Oncology ( CYAD ) +40% . Outset Medical ( OM ) +28% . Losers: Otonomy ( OTIC ) -77% . Kazia Therapeu...
ASHBURN, Va., July 28, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that it has received comprehensive and construc...
ASHBURN, Va., July 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has entered into the License and Distribution Agreement and the Supply Ag...
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada Canada NewsWire The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN , July 15, 2022 ...
ASHBURN, Va., July 06, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces that the first clinical site has now been fully opened for its ...
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty p...
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quart...
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to fourteen...